Many people suffer from dementia and other neurodegenerative conditions, and the number of patients keeps increasing. Unfortunately, little therapy is available for patients suffering from dementia, Alzheimer’s disease or other neurodegenrative diseases like Parkinson's.
The pharmaceutical companies are actively searching for improved therapies to help these patients. However, testing these new therapies in large clinical trials is very demanding. Pharmaceutical companies can rely on the ADx antibodies and services to accelerate and improve the design of clinical trials. The ADx technology and expertise help to design and develop the biomarkers that will allow to look for target engagement in pre-clinical development but also to screen, identify and follow up patients on a large scale in relevant clinical trials.
ADx helps pharmaceutical companies to forward therapeutic candidates from pre-clinical studies into clinical trials with its well designed biomarkers. ADx collaborates with pharmaceutical companies on a global scale. A first step in such a collaboration is to develop the antibodies and the needed assay. If an analytical reliable test is available we can then provide pre-clinical trial sample testing service (animal + human). Later on, test kits are upscaled and manufactured by our IVD partners in order to be used in the clinical trials.